Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001 exclusive licensing agreement.
In this interview Dr Dan Gooding outlines what the revised agreement covers, explains what it means for Nuformix and how it will benefit from NXP001 now and in the future, progressing its core NXP002 and NXP004 programmes and how Dan sees the outlook for the company.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing
The company uses their expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.
